Why the GLP 1 revolution must become part of a broader culture of food education family health and lifelong capability
Australia does not need to choose between modern medicine and healthy living. It needs a national strategy that uses medicine wisely while rebuilding people’s capacity to feed themselves and their families well for life.
The arrival of GLP-1 medicines has changed obesity treatment. Semaglutide, tirzepatide and related therapies can substantially reduce appetite and body weight, improve metabolic health and, for some high-risk patients, lower cardiovascular risk. These are important medical advances. They deserve neither dismissal nor exaggerated promises.
But we must ask a larger question. Are medicines that suppress appetite, often for as long as treatment continues, sufficient to create sustainable national health? My answer is no. They can be highly effective clinical tools, but medication alone cannot teach a family how to shop, cook and eat well. It cannot build strength, repair a food environment dominated by ultra-processed products, or give people the knowledge and confidence to manage their health when circumstances change.
If the GLP-1 revolution is to become a health revolution rather than simply a prescribing revolution, it must be joined to nutrition education, family-centred eating, muscle-preserving activity and continuing professional support.
The case for GLP-1 therapy is real. Clinical trials have demonstrated major weight reduction, and the SELECT trial showed that semaglutide reduced major cardiovascular events in people with established cardiovascular disease and overweight or obesity who did not have diabetes. For people living with severe obesity, diabetes, cardiovascular disease or intense biological hunger, treatment may be life-changing and, in some cases, appropriately long term.
The limitation is that the medication usually manages the biological drivers of appetite while it is being taken. It does not necessarily remove those drivers permanently. The STEP 1 extension found that participants regained about two-thirds of their prior semaglutide weight loss within one year of withdrawal, with several cardiometabolic improvements moving back towards baseline. In SURMOUNT-4, people switched from tirzepatide to placebo regained substantial weight, while those continuing treatment maintained and extended their loss.
This does not prove that the medicines have failed. It shows that obesity is frequently chronic and relapsing, and that many patients may require ongoing treatment. It also exposes the weakness of any system that supplies medication without simultaneously building lifelong capability. People need a plan for nourishment, strength and maintenance from the first prescription—not merely when the prescription ends.
A lower number on the scales can be valuable, but it is not the sole measure of wellbeing. During substantial weight loss, some lean tissue is commonly lost along with fat. That is not unique to GLP-1 therapy, but appetite suppression can make it harder for people to consume sufficient protein and micronutrients unless their meals are deliberately planned.
This matters particularly for older Australians. Muscle supports balance, independence, glucose control, recovery from illness and the ability to remain active. A person who becomes lighter but also weaker has not achieved the best possible health outcome.
Every medically supervised weight-loss pathway should therefore include:
· adequate high-quality protein, distributed across the day;
· progressive resistance exercise suited to the person’s age and ability;
· monitoring of strength, function and nutritional adequacy—not weight alone;
· whole foods that provide fibre, vitamins, minerals and lasting satiety; and
· review of side effects, medication interactions and the continuing need for treatment.
For some patients, ongoing medication will remain part of that pathway. For others, reduction or discontinuation may eventually be appropriate, but only in partnership with the prescriber and with a strong maintenance structure already in place.
Health is not created only in consulting rooms. It is created repeatedly in kitchens, supermarkets, schools, workplaces and family routines. This is why education and family-centred healthy eating are not soft additions to medical treatment. They are national health infrastructure.
When adults learn how protein, vegetables, healthy fats, minimally processed foods and sensible carbohydrate choices affect appetite and energy, that knowledge can influence an entire household. Children learn what an ordinary meal looks like. Partners support one another. Cooking skills, label literacy and better shopping habits become part of family culture rather than a temporary diet imposed on one individual.
A medicine can reduce hunger. Education can change what a person does when hungry, what food enters the home, how setbacks are handled and what the next generation regards as normal. The two can complement each other, but they are not interchangeable.
Australia should move beyond the false contest between medication and personal responsibility. Obesity is influenced by biology, genetics, sleep, mental health, medication, disadvantage and an environment engineered to encourage overconsumption. Education alone will not meet every clinical need; medication alone will not repair the conditions producing poor health.
A sustainable national approach should be built on seven commitments.
1 Treat obesity as a chronic health condition. Remove shame and provide proper clinical assessment. Treatment should be matched to risk, medical history and individual circumstances—not fashion, advertising or a single body-weight target.
2 Make food education part of standard care. Every person prescribed a weight-loss medicine should have access to practical instruction in meal construction, protein adequacy, shopping, cooking, appetite awareness and long-term maintenance.
3 Put families at the centre. Programs should help households create healthier routines together. National health improves when better eating becomes normal family life rather than an isolated five-week intervention.
4 Protect muscle and functional independence. Strength training, protein planning and functional monitoring should be core measures of success, especially for older adults—not optional advice at the bottom of a brochure.
5 Fund continuing human support. Pharmacists, dietitians, nutrition professionals, nurses, general practitioners and trained health coaches can provide accountability and early intervention. A prescription without follow-up is an incomplete service.
6 Require a maintenance and transition plan. From the beginning, every patient should know what continuing treatment may involve, what happens if it is interrupted and how weight regain will be addressed. Any reduction in medication should be medically supervised.
7 Reform the wider food environment. Governments must improve food literacy, protect children from harmful marketing, support access to nutritious food and encourage workplaces, schools and communities to make the healthier choice achievable.
Community pharmacies are well placed to turn GLP-1 dispensing into comprehensive weight and health management. They see patients regularly, understand their medicines and can identify inadequate nutrition, side effects, declining strength or early weight regain.
The opportunity is not merely to supply an injection. It is to offer a structured service that includes screening, education, real-food planning, appropriate referral, regular measurement and coordination with the prescriber. This creates better continuity for the patient and a responsible professional service for the pharmacy.
Programs such as UltraLite can contribute by providing structured education, whole-food principles, accountability and an on-treatment or post-treatment pathway. The claim should never be that every person can or should abandon medication. The promise should be that no person is left dependent on medication without also receiving the skills required to nourish and care for themselves.
The World Health Organization’s 2025 guidance reflects this balance. It conditionally supports GLP-1 therapies for long-term obesity treatment, while emphasising comprehensive, lifelong care that includes healthy diets, physical activity and professional support. The recommendation remains conditional because uncertainties persist regarding very long-term safety and effectiveness, discontinuation, cost, health-system readiness and equitable access.
Australia should embrace the benefits of GLP-1 medicines without allowing them to become a substitute for public-health leadership. If we define success only by kilograms lost or prescriptions dispensed, we will miss the larger task. Sustainable health means people who understand food, retain muscle, remain active, participate in family life and possess the confidence to manage their wellbeing over decades.
The medicine may quiet the appetite. It is education, real food, family support, physical strength and personal capability that build a healthier nation.
· World Health Organization 2025 guideline on GLP 1 medicines and obesity
· Weight regain after withdrawal of semaglutide in the STEP 1 trial extension
· Continued treatment and withdrawal in the SURMOUNT 4 tirzepatide trial